Contact Us
Please Contact Us

toll free: 1800 3070 6727    Email Id:

BRACAnalysis CDx is an FDA-approved companion diagnostic test for BRCA1 and BRCA2 intended to be used as an aid in treatment decision making for olaparib, a PARP inhibitor

BRACAnalysis CDx is the first and only FDA-approved laboratory developed test (LDT) that indicates whether or not a patient with ovarian cancer may be eligible for treatment with the PARP inhibitor Olaparib.

With the introduction of PARP inhibitors, BRCA mutation testing is critical in ovarian cancer patients to identify the subset of women who might benefit from this therapy choice.

BRCA testing can be done on blood, saliva or tumour. BRACAnalysisCDX is done on tumour. Testing the tumor rather than blood or saliva for the mutation identifies 50% more patients with :

  • A BRCA1 or BRCA2 mutation

  • Helps more ovarian cancer patients understand their treatment options

  • Identifies 50% more patients with BRCA-mutated ovarian cancer compared to testing via blood or saliva

  • My mother had ovarian cancer. After taking cisplatin we were looking for a therapy to maintain her response. We underwent BRACAnalysisCDX which was positive in her case  and we started giving her Olaparib.


Reports provides information that allows physicians to:

  • Better understand a patients’ risk for specific health conditions

  • Prescribe more suitable medications at optimal dosages for patients, as needed.

  • Suggest early lifestyle and diet interventions to help control or prevent certain health conditions.

Related Test

  • protect-25

    Best treatment recommendation

    Provides information on pathway analysis

    Includes Positive Bioscience expert comments and complementary consulation with your docto

    INR 165750
    INR 195000

  • myrisk

    65% increase in median overall survival

    Multiple technology platform to provide most comprehensive recommendations

    Complimentary consultation

    INR 497250
    INR 585000

  • health_plus

    31% more accurate in identifying cancer driver mutations

    Better treatment recommendation

    Complementary consultation with your doctor

    INR 93925
    INR 110500

Copyright ©2017 Positive Bioscience, Inc. All Rights Reserved